Meattini Icro, Saieva Calogero, Meacci Fiammetta, Scotti Vieri, De Luca Cardillo Carla, Desideri Isacco, Baldazzi Valentina, Mangoni Monica, Scoccianti Silvia, Detti Beatrice, Simontacchi Gabriele, Nori Jacopo, Orzalesi Lorenzo, Sanchez Luis, Casella Donato, Bernini Marco, Fambrini Massimiliano, Bianchi Simonetta, Livi Lorenzo
Department of Radiation Oncology, University of Florence, Florence, Italy.
Molecular & Nutritional Epidemiology Unit, Cancer Research & Prevention Institute (ISPO), University of Florence, Florence, Italy.
Future Oncol. 2016 Mar;12(5):625-35. doi: 10.2217/fon.15.357. Epub 2016 Feb 3.
This study analyzes our single-center, retrospective experience on 63 premenopausal breast cancer patients treated with monthly triptorelin and concomitant chemotherapy.
PATIENTS & METHODS: Concomitant chemotherapy and triptorelin were adopted as part of premature ovarian failure prevention strategy.
Age at diagnosis was the main factor influencing fertility preservation (p = 0.002). Compared with patients aged 41-45 years, the probability of menses resumption was almost threefold than for women aged 35-40 years, and significantly higher for women aged <35 years (hazard ratio: 9.0; p = 0.0001). The cumulative proportion among patients who resumed menses was 33.3% at 6 months, 75% at 12 months and 87.5% at 24 months. Seven patients attempted pregnancy, and five (71%) obtained healthy deliveries.
We observed an acceptable rate of fertility preservation. Age at diagnosis influences fertility preservation.
本研究分析了我们单中心对63例接受每月一次曲普瑞林联合化疗的绝经前乳腺癌患者的回顾性经验。
采用联合化疗和曲普瑞林作为预防卵巢早衰策略的一部分。
诊断时的年龄是影响生育力保留的主要因素（p = 0.002）。与41 - 45岁的患者相比，月经恢复的概率几乎是35 - 40岁女性的三倍，而<35岁女性的月经恢复概率显著更高（风险比：9.0；p = 0.0001）。月经恢复患者的累积比例在6个月时为33.3%，12个月时为75%，24个月时为87.5%。7例患者尝试怀孕，其中5例（71%）顺利分娩。
我们观察到生育力保留率可以接受。诊断时的年龄影响生育力保留。
